George A. Komatsoulis, Ph.D., Joins CancerLinQ LLC as Chief of Bio-Informatics

For immediate release
December 5, 2016

Contact

Kate Crawford
(571) 483-1366
Dr. George A. Komatsoulis

George A. Komatsoulis, Ph.D., will be CancerLinQ LLC's first Chief of Bio-Informatics

ALEXANDRIA, Va. -- CancerLinQ LLC, a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO®), has announced that George A. Komatsoulis, Ph.D., will be its first Chief of Bio-Informatics. This marks another step toward the organization's goal of making the CancerLinQ® platform the premier system for unlocking patient data from millions of electronic health records (EHR), breaking down silos among various EHR systems and providers, and securely processing and analyzing the data to give personalized insights than can improve the quality of care for patients with cancer.

"With more than 1.5 million records in the system and more being inputted every day, the CancerLinQ platform is now in a position to analyze and discover insights and trends that can improve cancer care," said CancerLinQ LLC Chief Executive Officer Kevin Fitzpatrick. "We are excited to have Dr. Komatsoulis joining the CancerLinQ team to lead this effort that is vital to improving cancer care."

Komatsoulis will serve in this new role and joins ASCO after more than 20 years of experience in the fields of information technology and biomedical informatics. Prior to joining the CancerLinQ team, he spent 12 years in senior positions at the National Institutes of Health (NIH). During that time, he served as the Deputy and Interim Director of the National Cancer Institute (NCI) Center for Biomedical Informatics and Information Technology (CBIIT), Chief Information Officer at the NCI, and Acting Chief of the Informatics Resources Branch at the National Center for Biotechnology Information. Komatsoulis' work at the NIH focused on bringing advanced information technology capabilities to the biomedical research community, most recently cloud computing via the NCI's Cancer Genomics Cloud Pilots and the NIH Commons Credits Model programs. He also has experience in the commercial sector in the Bioinformatics Department at Human Genome Sciences, Inc. Komatsoulis holds a Ph.D. in molecular biology and biochemistry from the California Institute of Technology and a B.S. in microbiology from Cornell University.

CancerLinQ is a powerful platform containing growing amounts of real-world cancer information. This national initiative will allow cancer providers to improve the quality and value of care by analyzing millions of cancer patient medical records, uncovering patterns and trends, and measuring their care against that of their peers and recommended guidelines.

In October, ASCO announced that CancerLinQ had, at that point, more than one million patient records in its system, as well as more than 70 practices that had signed agreements to participate, representing more than 1,500 oncologists.

CancerLinQ is supported in part through the Conquer Cancer Foundation, whose generous donors have helped make the system possible. Major supporters include Amgen; Astellas; AstraZeneca; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Cancer Treatment Centers of America®; Chan Soon-Shiong Family Foundation; Genentech BioOncology™; HELSINN; Janssen Oncology; Lilly; Novartis Oncology; Pfizer Oncology; Raj Mantena, RPh; Susan G. Komen®; and Thomas G. Roberts, Jr., MD, and Susan M. DaSilva.

CancerLinQ is a project of CancerLinQ LLC. For more information on how to participate or partner with CancerLinQ, please visit CancerLinQ.org

About ASCO: 

Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. As the world’s leading organization of its kind, ASCO represents more than 40,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. Learn more at www.ASCO.org, explore patient education resources at www.Cancer.Net, and follow us on Facebook, Twitter, LinkedIn, and YouTube.

About CancerLinQ LLC
CancerLinQ LLC is a subsidiary of American Society of Clinical Oncology, Inc. established for the development and operation of the CancerLinQ™ initiative. CancerLinQ™ is a health information technology platform aimed at enhancing and improving the understanding and treatment of cancer. To learn more, visit www.cancerlinq.org.